Scientific and Regulatory Policy Committee points to consider: nonclinical research and development of in vivo gene therapy products, emphasizing adeno-associated …

JA Hutt, BT Assaf, B Bolon, J Cavagnaro… - Toxicologic …, 2022 - journals.sagepub.com
Sequencing of the human genome and numerous advances in molecular techniques have
launched the era of genetic medicine. Increasingly precise technologies for genetic …

Considerations for preclinical safety assessment of adeno-associated virus gene therapy products

BT Assaf, LO Whiteley - Toxicologic Pathology, 2018 - journals.sagepub.com
Progress in understanding the molecular bases of human health and disease in recent
decades has flourished making it possible for the field of gene therapy (GT) to offer new …

Preclinical development strategies for novel gene therapeutic products

AM Pilaro, MA Serabian - Toxicologic pathology, 1999 - journals.sagepub.com
With over 220 investigational new drug applications currently active, gene therapy
represents one of the fastest growing areas in biotherapeutic research. Initially conceived for …

Safety of gene therapy: new insights to a puzzling case

M Rothe, A Schambach, L Biasco - Current gene therapy, 2014 - ingentaconnect.com
Over the last few years, the transfer of therapeutic genes via gammaretro-or lentiviral vector
systems has proven its virtue as an alternative treatment for a series of genetic disorders …

Bioanalysis of adeno-associated virus gene therapy therapeutics: regulatory expectations

B Gorovits, JC Marshall, J Smith, LO Whiteley… - Bioanalysis, 2019 - Taylor & Francis
The number of gene therapy (GTx) modality therapies in development has grown
significantly in the last few years. Adeno-associated virus (AAV)-based delivery approach …

Nonclinical studies that support viral vector-delivered gene therapies: an EFPIA gene therapy working group perspective

MW Bolt, LO Whiteley, JL Lynch, B Lauritzen… - … Therapy-Methods & …, 2020 - cell.com
Nonclinical development strategies for gene therapies are unique from other modalities. The
European Federation of Pharmaceutical Industries and Associates (EFPIA) Gene Therapy …

Food and drug administration guidance on design of clinical trials for gene therapy products with potential for genome integration or genome editing and associated …

D Eisenman, S Swindle - Applied Biosafety, 2022 - liebertpub.com
Introduction: With the burgeoning growth of the gene therapy industry, the Food and Drug
Administration (FDA) has produced various guidance documents intended to help gene …

Gene therapy for cancer: regulatory considerations for approval

SR Husain, J Han, P Au, K Shannon, RK Puri - Cancer gene therapy, 2015 - nature.com
The rapidly changing field of gene therapy promises a number of innovative treatments for
cancer patients. Advances in genetic modification of cancer and immune cells and the use of …

A changing world in gene therapy research: Exciting opportunities for medical advancement and biosafety challenges

D Eisenman, S Debold, J Riddle - Applied Biosafety, 2021 - liebertpub.com
Introduction: We previously reported on the United States' regulatory environment evolving
to accommodate an emerging boom in gene therapy research. Several important …

The United States' regulatory environment is evolving to accommodate a coming boom in gene therapy research

D Eisenman - Applied Biosafety, 2019 - liebertpub.com
Introduction: A dramatic increase in the number of clinical trials involving gene-modified cell
therapy and gene therapy is taking place. The field is on the verge of a boom, and the …